tivo-3: tivozanib hydrochloride vs sorafenib for refractory advanced rcc
Published 2 years ago • 136 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:41
tivozanib tolerability shows potential advantage for patients with advanced rcc
-
1:28
dr. motzer on the tivo-3 trial examining tivozanib in advanced rcc
-
2:42
latest from tivo-3: tivozanib for refractory advanced renal cell carcinoma
-
4:18
tivozanib for refractory advanced rcc
-
0:52
dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
-
4:07
tivo-3 results point to tivozanib activity after rcc progression on axitinib | brian rini
-
2:43
adverse effect profile for tivozanib plus sorafenib for relapsed/refractory renal cell carcinoma
-
1:15
dr. vaishampayan on the safety of tivozanib versus sorafenib in rcc
-
30:36
bispecific antibodies to engage vγ9vδ2-t cells for cancer immunotherapy
-
4:37
what are trispecific antibodies?
-
44:23
beyond single-cell resolution: high-plex 3d profiling of tissues and tumors l prof. peter sorger
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc
-
12:49
the tivo-3 study of tivozanib in metastatic renal cell carcinoma
-
2:16
further evaluation of tivozanib shows promise for relapsed, refractory renal cell carcinoma
-
0:33
rana mckay, md, offers impressions of the tivo-3 study in highly refractory advanced rcc patients
-
1:00
dr. vaishampayan on the potential of tivozanib in advanced rcc
-
0:59
data support use of tivozanib in patients with advanced renal cell carcinoma
-
1:20
tivozanib
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
1:15
tivozanib could evaluated in combination regimens for renal cell carcinoma
-
2:06
dr. rini discusses tivozanib in advanced rcc
-
2:07
dr. subbiah on the importance of tivozanib in rcc